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Stringent control of NF-kB and mitogen-activated
protein kinase (MAPK) signaling is critical during
innate immune responses. TGF-b activated kinase-1
(TAK1) is essential for NF-kB activation in T and B
cells but hasprecisely theopposite activity inmyeloid
cells. Specific deletion of TAK1 (Map3k7DM/DM) led to
development of splenomegaly and lymphomegaly
associated with neutrophilia. Compared with wild-
type cells, TAK1-deficient neutrophils enhanced the
phosphorylation of the kinases IKK, p38, and JNK
and the production of interleukin-1b (IL-1b), IL-6,
tumor necrosis factor-a (TNF-a), and reactive oxygen
species (ROS) after lipopolysaccharide (LPS) stimu-
lation. Map3k7DM/DM mice were significantly more
susceptible to LPS-induced septic shock and pro-
duced higher amounts of IL-1b, IL-6, and TNF-a in
plasma than do wild-type mice. Specific ablation of
p38 rescued the phenotype and functional properties
of Map3k7DM/DM mice. Our findings identify a previ-
ously unrecognized role of TAK1 as a negative regu-
lator of p38 and IKK activation in a cell type-specific
manner.
INTRODUCTION
Recognition of cytokines and pattern-associated molecular
patterns (PAMPs) by innate immune receptors triggers immune
responses involving several signaling molecules (Han and
Ulevitch, 2005; Hayden and Ghosh, 2008; Kawai and Akira,
2007). Transforming growth factor-b activated kinase-1 (TAK1,
Map3k7), a member of the mitogen-activated protein kinase
kinase kinase (MAP3K) family, is essential in innate and adaptive
immune signaling cascades (Ninomiya-Tsuji et al., 1999; Wang
et al., 2001). TAK1 activation is triggered by diverse stimuli in-
cluding proinflammatory cytokines such as interleukin-1 (IL-1),
tumor necrosis factor (TNF), and Toll-like receptor (TLR) ligands
and culminates in downstream activation of nuclear factor-kB(NF-kB), p38, JNK, and ERK mitogen-activated protein kinase
(MAPK) signaling pathways (Adhikari et al., 2007; Shim et al.,
2005). Activation of the NF-kB pathway is initiated by ligand acti-
vation of TLRs or IL-1 receptor (IL-1R) resulting in recruitment of
adaptor proteins including MyD88, IRAK1, IRAK4, and TRAF6 to
the Toll-IL-1R homology cytoplasmic domain of the receptors
(Kawai and Akira, 2007). TAK1 with its associated proteins
TAB1, TAB2, and TAB3 play a pivotal role in activating IkB kinase
(IKK) and MAPK signaling cascades (Adhikari et al., 2007; Bhoj
and Chen, 2009). Recent studies have defined an essential role
of TAK1 in T cell receptor (TCR)- and B cell receptor (BCR)-
induced activation of NF-kB and in the survival and development
of immune cells, including mature B cells and T cells (Liu et al.,
2006; Sato et al., 2005, 2006; Schuman et al., 2009; Tang
et al., 2008; Wan et al., 2006). In B cells, TAK1 is required for B
cell development and NF-kB and MAPK activation induced by
cytokines, TLR ligands, and BCR stimuli (Sato et al., 2005; Schu-
man et al., 2009). T cell-specific ablation of TAK1 impairs T cell
survival in the periphery and TAK1 is also essential for TCR-
mediated NF-kB and MAPK activation (Liu et al., 2006; Sato
et al., 2006; Wan et al., 2006). Multilineage hematopoietic cell
survival also requires TAK1 as indicated by studies where
TAK1 deletion triggers uncontrolled apoptosis in hematopoietic
cells (Tang et al., 2008). However, the specific function, if any,
of TAK1 in myeloid cell development and TLR-induced innate
immunity remains largely unknown.
The mammalian innate immune system is evolutionarily
conserved and serves as an initial defense mechanism against
harmful pathogens by activating immune cells such as macro-
phages, neutrophils, and dendritic cells (Akira et al., 2006).
Myeloid cells (Gr-1+CD11b+ neutrophils and F4/80+CD11b+
macrophages) arise from common myeloid and granulocyte-
monocyte progenitors and are crucial for mounting effective
host defense against microbial invasion (Geissmann et al.,
2010). Neutrophils and macrophages function as professional
phagocytic cells that mediate host defense by recognizing and
destroying foreign infectious pathogens (Kantari et al., 2008).
Pattern recognition receptors of the innate immune system in-
cluding TLR that are expressed by myeloid cells are critical for
immune surveillance, pathogen recognition, and activation of
proinflammatory pathways (Janeway and Medzhitov, 2002).
After recognition of microbial pathogens by myeloid cells,Immunity 36, 43–54, January 27, 2012 ª2012 Elsevier Inc. 43
Figure 1. Characterization andPhenotypic Analysis ofMap3k7DM/DM
Mice
(A) PCR analysis of Map3k7 deletion with macrophages from WT and
Map3k7DM/DM mice.
(B) Immunoblot analysis of TAK1 protein expression with anti-TAK1 in
macrophages, B cells, T cells, and neutrophils.
(C) Lymphadenopathy in Map3k7DM/DM mice compared with WT control.
Inguinal (i), axillary (ii), superficial cervical (iii), and mesenteric (iv) lymph nodes
were examined.
(D) H&E staining of spleen sections from WT and Map3k7DM/DM mice.
Data shown are representative of at least five independent experiments. See
also Table S1 and Figure S1.
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TAK1 Inhibits NF-kB and p38 Signaling in Neutrophilsproinflammatory cytokines such as IL-6, TNF-a, IL-1, IL-12,
IL-15, and IL-18 (Cohen, 2006) are released that initiate and
amplify inflammatory signaling cascades. Because of the im-
portance of myeloid cells in innate and adaptive immunity, in
the present study we describe a role for TAK1 as a negative
rather than a positive regulator of NF-kB and MAPK signaling
in neutrophils. Myeloid cell-specific TAK1 deletion resulted in
splenomegaly and enlargement of lymph nodes and enhanced
rather than reduced the phosphorylation of IKK, p38, and JNK.
Consistent with these results, TAK1-deficient mice produced
larger amounts of proinflammatory cytokines and were more
susceptible to LPS-induced septic shock compared to wild-
type (WT) mice. Importantly, we provide genetic evidence that
specific deletion of p38a in myeloid cells rescued the pheno-
types and functional properties observed in TAK1-deficient
mice. We also have shown that three distinct mechanisms are
involved in p38 activation. These results identify a previously
unrecognized role of TAK1 as a cell type-specific negative regu-
lator of the TLR4-induced NF-kB and p38 signaling pathways
during myeloid cell homeostasis.
RESULTS
Generation and Characterization of Myeloid
Cell-Specific TAK1-Deficient Mice
To investigate the role of TAK1 in myeloid lineage development
and innate immune response, we specifically ablated TAK1 in
myeloid cells by crossingMap3k7flox/flox micewithmice express-
ing the lysozyme promoter-driven cre recombinase gene (Lyz2-
Cre). The resultant heterozygous Map3k7flox/+ 3 Lyz2-Cre and
homozygous Map3k7flox/flox 3 Lyz2-Cre mice were designated
Map3k7DM/+ and Map3k7DM/DM mice, respectively. Selective
deletion of Map3k7 in myeloid cells of Map3k7DM/DM mice was
demonstrated by polymerase chain reaction (PCR) and immuno-
blot analyses (Figures 1A and 1B). Although there were no
phenotypic or functional differences between wild-type (WT)
Map3k7+/+ and heterozygous Map3k7DM/+ mice, Map3k7DM/DM
mice developed splenomegaly (data not shown) and profound
enlargement of all lymph nodes (LNs) (Figure 1C). Gross
examination of tissues showed that spleens and LNs from
Map3k7DM/DM mice were at least three times larger than those
from control mice. The total number of splenocytes and the
weight of spleens were markedly increased in Map3k7DM/DM
mice (Figures S1A and S1B available online). Histological anal-
ysis revealed extramedullary hematopoiesis in the spleens of
Map3k7DM/DM mice (Figure 1D, top). Splenic architecture was
grossly disorganized, with loss of the marginal zone barrier and
massive myeloid hyperplasia in the red pulp (Figure 1D, bottom).
Hematologic analysis of peripheral blood in Map3k7DM/DM mice
revealed leukocytosis and granulocytosis but decreased eryth-
ropoiesis and hemoglobin (Table S1).
Loss of TAK1 Increases the Proliferative Activity of
Neutrophils but Promotes Apoptosis in Macrophages
Flow cytometric analysis of different cell populations in the bone
marrows and spleens from WT and TAK1-deficient mice indi-
cated that the percentages of Gr-1+CD11b+ neutrophils were
markedly increased in the bone marrow and spleen (Figures 2A
and 2B). The percentages of F4/80+CD11b+ macrophages44 Immunity 36, 43–54, January 27, 2012 ª2012 Elsevier Inc.were also increased in TAK1-deficient spleens (Figure 2B).
Bone marrow smears revealed an increase in immature neutro-
phils in Map3k7DM/DM mice compared to WT mice (Figure 2C).
These results indicate that Gr-1+CD11b+ neutrophils are strik-
ingly increased in Map3k7DM/DM mice, in contrast to the reduc-
tion of T cells or mature B cells observed in mice with specific
ablation of TAK1 in lymphoid cells (Liu et al., 2006; Sato et al.,
2005, 2006; Schuman et al., 2009;Wan et al., 2006) and in hema-
topoietic cells (Tang et al., 2008). Because myeloid-derived
suppressor cells (MDSC) expressing Gr-1 (Ly-6C and/or Ly-6G)
and CD11b molecules are known to dampen immune response
by inhibiting CD4+ and CD8+ T lymphocyte function in cancer
(Marigo et al., 2008), we tested whether Gr-1+CD11b+ cells in
Map3k7DM/DM mice had suppressive function. A T cell prolifer-
ation assay showed that Gr-1+CD11b+ cells isolated from
Map3k7DM/DM mice had no suppressive effect on naive CD4+
T cell proliferation (Figure S1C).
Consistent with the results of blood counts (Table S1), splenic
CD3+ T and B220+ B cell populations were comparable between
Map3k7DM/DM and WT mice (Figure 2D). We further investigated
whether the development of splenomegaly and lymphomegaly in
Map3k7DM/DMmice affected T cell activation in the periphery and
found that both activated (CD69+ or CD44+) T cell populations
were elevated in the spleens and LNs of Map3k7DM/DM mice
compared with WT mice (Figures S1D and S1E). Intracellular
staining revealed that interferon-g (IFN-g)-producing CD4+ and
Figure 2. TAK1 Ablation Increases Gr-1+CD11b+ Neutrophils in the
Bone Marrow and Spleen
(A and B) Flow cytometric analysis of Gr-1+CD11b+ neutrophil and
F4/80+CD11b+ macrophage populations in bone marrow (A) and spleen (B) of
WT and Map3k7DM/DM mice, with anti-Gr-1, anti-F4/80, and anti-CD11b.
Results plotted as mean ± SD. **p < 0.01. BM, bone marrow; SP, spleen.
(C) Bone marrow smear and Wright-Giemsa staining of bone marrow cells
visualized by light microscopy.
(D) T and B lymphocyte analysis in spleen via anti-CD3 and anti-B220 staining
and flow cytometry.
Results are representative of at least four independent experiments. See also
Figure S1.
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TAK1 Inhibits NF-kB and p38 Signaling in NeutrophilsCD8+ T cells were also increased in the spleens and LNs of
Map3k7DM/DMmice compared with WTmice (Figure S1F). These
data suggest that TAK1 deletion in myeloid cell lineage does not
alter the numbers of T cells, but markedly increases the activated
T cell population inMap3k7DM/DM mice, probably because of the
proinflammatory cytokine environment.
To determine whether cell proliferation or apoptosis ac-
counted for the observed differences in myeloid cell numbers
between Map3k7DM/DM and WT mice, bromodeoxyuridine
(BrdU) pulse labeling and flow cytometry were performed. The
results in Figures 3A and 3B show that BrdU-positive prolifer-
ating Gr-1+CD11b+ cells were dramatically increased in bone
marrows and spleens of TAK1-deficient mice compared with
WT mice, suggesting that TAK1 deletion increases the prolifera-
tion of neutrophils. Consistent with these observations, immuno-
histochemical staining of spleen sections with anti-CD11b
and anti-Ki-67 showed that the numbers of CD11b-positive orKi-67-positive cells were much higher in Map3k7DM/DM than in
WT mice (Figure 3C). Because TAK1 ablation in T cells, hemato-
poietic cells, intestinal epithelia, keratinocytes, and hepatocytes
increases apoptosis (Bettermann et al., 2010; Inokuchi et al.,
2010; Kajino-Sakamoto et al., 2008; Liu et al., 2006; Omori
et al., 2006; Sato et al., 2006; Schuman et al., 2009; Tang
et al., 2008; Wan et al., 2006), we examined the effect of TAK1
loss on myeloid cell survival in vitro and in vivo. We did not
observe any difference in terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL)-positive cells in spleen sections
between Map3k7DM/DM and WT mice (Figure 3C). Annexin V
staining and flow cytometry analysis of gated Gr-1+CD11b+ cells
also showed equal or less apoptosis in neutrophils from spleen
and bone marrow of Map3k7DM/DM mice compared with WT
mice (Figures 3D and 3E), suggesting that TAK1 deletion had
amajor effect on neutrophil proliferation but not on its apoptosis.
We next examined the survival of cultured bone marrow-
derived macrophages (BMM) from Map3k7DM/DM and WT mice
and found that BMM from TAK1-deficient mice died after
3 days of culture (Figures 3F and 3G), even with different
amounts of conditioned medium (Figure S2A). It appeared that
apoptosis mainly contributed to cell death or the reduction of
cell numbers (Figures S2A and S2B), because carboxyfluores-
cein succinimidyl ester (CFSE)-labeling experiments showed
that the viable TAK1-deficient differentiating cells divided only
slightly slower than did WT cells (Figure S2C). In contrast, we
did not observe increased apoptosis in neutrophils cultured in
medium with or without granulocyte-colony stimulating factor
(G-CSF) (Figure S2D). These results suggest that TAK1 loss
enhances the proliferation and growth of neutrophils but causes
increased apoptosis in macrophages. Because TAK1-deficient
BMM undergo apoptosis, we used freshly isolated peritoneal
macrophages for further experiments, because there was no
difference in cell survival between freshly isolated WT and
TAK1-deficient cells (Figure S2E).
TAK1Negatively Regulates IKK, p38, and JNKActivation
in Neutrophils
To determine the function of TAK1 in innate immune signaling
pathways in myeloid cells, we isolated neutrophils from WT
and Map3k7DM/DM mice, treated them with LPS, and performed
immunoblot analysis with specific antibodies. We unexpectedly
found that IKK phosphorylation was enhanced and remained
high for a sustained period in TAK1-deficient neutrophils,
compared withWT cells (Figure 4A). Consistently, IkBa degrada-
tion was more robust in Map3k7DM/DM cells compared to WT
cells (Figure 4A). More importantly, we found that phosphoryla-
tion of p38 and JNK was also markedly enhanced rather than
reduced in LPS-treated TAK1-deficient neutrophils, compared
with WT cells (Figure 4A). In contrast, there was no appreciable
increase in phosphorylation of ERK between TAK1-deficient
and WT cells (Figure 4A). Densitomeric quantification of these
results is shown in Figure 4A. Phosphorylation of IKK, p38,
JNK, and ERK was comparable or slightly reduced in TAK1-
deficient macrophages, compared with WT cells after LPS stim-
ulation (Figure 4B). Similarly, IkBa degradation was also slightly
reduced inMap3k7DM/DM cells compared toWT cells (Figure 4B).
Consistent with previous findings with TAK1-null mouse embry-
onic fibroblasts (MEFs) (Sato et al., 2005; Shim et al., 2005),Immunity 36, 43–54, January 27, 2012 ª2012 Elsevier Inc. 45
Figure 3. Proliferation and Apoptosis Analyses of
TAK1-Deficient Neutrophils and Macrophages
(A and B) BrdU pulse labeling of mice and flow cytometric
analysis of bone marrow (A) and spleen (B) cells via anti-
BrdU. Gr-1+CD11b+ cells were gated to determine the
percentage of BrdU-positive cells.
(C) Immunohistochemistry was performed on spleen
tissues with anti-CD11b and anti-Ki-67, and TUNEL
staining was done to detect apoptotic cells.
(D–F) Apoptosis was assayed with Annexin V/7-AAD
apoptosis staining and flow cytometry analysis of bone
marrow (D), spleen (E), and bone-marrow-derived mac-
rophages (BMM) cultured with 10% M-CSF conditioned
medium (F). Gr-1+CD11b+ bone marrow and spleen cells
and F4/80+CD11b+ BMM cells were gated to determine
percentage of apoptotic cells.
(G) Photographs of BMM were visualized by light
microscopy.
Results are representative of at least five independent
experiments. See also Figure S2.
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TAK1 Inhibits NF-kB and p38 Signaling in Neutrophilswe found that phosphorylation of IKK, p38, JNK, and ERK was
completely abolished in TAK1-deficient MEFs, compared to
WT MEFs (Figure 4C). Taken together, these data indicate
that TAK1 acts as a negative regulator of NF-kB, p38, and JNK
activation in neutrophils.
To further assess expression of downstream NF-kB-respon-
sive cytokine genes, we performed real-time PCR analysis and
found that expression of IL-6, TNF-a, and IL-1b mRNA was
markedly increased in TAK1-deficient neutrophils compared
with WT cells (Figure 4D). By contrast, mRNA expression of
these genes inMap3k7DM/DM macrophages was similar or lower
than those in WT cells (Figure S2F). Furthermore, pro-IL-1b
protein expression was increased in Map3k7DM/DM neutrophils
compared with WT cells, but no difference was observed
between Map3k7DM/DM macrophages and WT cells (Figure 4E).
These results suggest that TAK1 ablation increases NF-kB,
p38, and JNK signaling as well as expression of their down-
stream target cytokine genes in neutrophils.46 Immunity 36, 43–54, January 27, 2012 ª2012 Elsevier Inc.TAK1 Deletion Enhances
Proinflammatory Cytokine Production
in Neutrophils
Given these unexpected findings, we reasoned
that TAK1-deficient neutrophils would produce
more proinflammatory cytokines than control
cells after LPS treatment. Indeed, neutrophils
from Map3k7DM/DM mice produced significantly
more IL-6 and TNF-a than those from WT mice
(Figure 5A). Because IL-1b release requires the
processing of pro-IL-1b by inflammasome-
activated capsase-1 (Schroder and Tschopp,
2010), we measured IL-1b secretion from WT
and TAK1-deficient neutrophils after LPS with
or without ATP treatment. Although neutrophils
could produce IL-1b after LPS treatment alone,
LPS plus ATP treatment markedly increased
IL-1b production inWT and TAK1-deficient cells
(Figures 5A and S2G). Furthermore, TAK1-
deficient neutrophils produced significantly
more IL-1b than did WT cells after LPS treat-ment with or without ATP (Figures 5A and S2G). By contrast,
peritoneal macrophages from TAK1-deficient mice produced
similar amounts of IL-6 and lower amounts of TNF-a than found
in WT cells after LPS treatment (Figure 5B). Although neither WT
nor TAK1-deficient peritoneal macrophages secreted IL-1b after
LPS treatment alone, TAK1-deficient peritoneal macrophages
produced more IL-1b than WT controls after LPS plus ATP treat-
ment (Figures 5B and S2G), suggesting that activation of in-
flammasome-mediated capsase-1 by ATP is required for IL-1b
secretion frommacrophages. In contrast toWTMEF cells, which
produced robust amounts of IL-6 after LPS treatment, TAK1-
deficientMEF cells failed to release IL-6 after LPS treatment (Fig-
ure 5C), further suggesting that TAK1 functions differently in
a cell type-specific manner.
To gain further insight into the physiological function of TAK1,
we injected WT andMap3k7DM/DM mice with a high dose of LPS
(30 mg/kg) and monitored their survival. Eighty percent of
Map3k7DM/DM mice died from LPS-induced endotoxic shock
Figure 4. Effects of Map3k7 Ablation on
NF-kB and MAPK Signaling Pathways Is
Cell Type Specific
(A–C) WT or TAK1-deficient neutrophils (A), peri-
toneal macrophages (B), or MEFs (C) were treated
with LPS for the indicated time points, followed
by immunoblot analysis of phosphorylated IKK
(P-IKK), P-p38, P-JNK, P-ERK, p38, and IkBawith
cell lysates.
(A) Right: Quantitative comparison of activation of
signaling molecules between WT orMap3k7DM/DM
neutrophils by densitometric scanning of blots.
(D) IL-6, TNF-a, and IL-1b mRNA expression in
neutrophils treated with LPS (100 ng/ml) for indi-
cated time points determined by real-time PCR.
Results are plotted as mean ± SD. *p < 0.05; **p <
0.01; ***p < 0.001.
(E) Immunoblot analysis of pro-IL1b in neutrophils
and macrophages treated with LPS for 2 hr and
6 hr, respectively.
Results are representative of at least five inde-
pendent experiments. See also Figure S2.
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TAK1 Inhibits NF-kB and p38 Signaling in Neutrophilswithin 10 hr, compared to only 25% of the WT group, whereas
the remaining mice survived for up to 40 hr after LPS treatment
(Figure 5D). Consistent with this observation, Map3k7DM/DM
mice had markedly elevated serum concentrations of proin-
flammatory cytokines such as IL-6, TNF-a, and IL-1b after
LPS treatment, compared with WT mice (Figure 5E). To exclude
the possibility that macrophages contribute to susceptibility of
Map3k7DM/DM mice to LPS, we depleted macrophages in
Map3k7DM/DM mice with clodronate-containing liposomes fol-
lowed by LPS treatment and found no difference in LPS-induced
septic shock in mice treated with control liposomes and clodro-
nate (Figure S2H), suggesting that macrophagesmay not be crit-
ical in LPS-induced septic shock in Map3k7DM/DM mice. These
results provide in vivo evidence that TAK1 deletion in myeloid
cells enhances the sensitivity and severity of LPS-induced septic
shock and is associated with increased serum concentrations of
proinflammatory cytokines, reinforcing the apparent role of TAK1
as a negative regulator of innate immune response.
Genetic Ablation of p38 in Myeloid Cells Rescues
the Phenotypes of Map3k7DM/DM Mice
It has been reported that downregulation of NF-kB activation, re-
sulting from IKKb (encoded by Ikbkb) deficiency in myeloid cells,
enhances IL-1b production through a caspase-1-independent
mechanism that modulates NF-kB-dependent expression of
protease inhibitors in neutrophils (Greten et al., 2007). However,
this mechanism could not explain the enhanced production ofImmunity 36, 43–5IL-1b in Map3k7DM/DM neutrophils,
because IKK activation was increased
rather than decreased in these cells after
LPS treatment. Furthermore, this pro-
posed mechanism does not account for
the aberrant production of IL-6 and
TNF-a in neutrophils. Because TAK1
ablation markedly enhances activation
of p38, which is known to play a crucial
role in inflammatory responses and trans-lational regulation of IL-1b, IL-6, and TNF-a (Han and Ulevitch,
2005; Kang et al., 2008), we reasoned that specific deletion of
p38 (encoded byMapk14) could rescue the phenotype and func-
tion ofMap3k7DM/DM mice. To test this possibility, we generated
Map3k7flox/flox 3 Mapk14flox/flox 3 Lyz2-Cre double-deletion
(Map3k7DM/DMMapk14DM/DM) mice. Both PCR and immunoblot
analyses confirmed the deletion of TAK1 and p38 in macro-
phages and neutrophils (Figures S3A–S3C). Gross phenotypic
analysis revealed that the spleen size of Map3k7DM/DM
Mapk14DM/DM mice was reduced to a size comparable to WT
spleen, thus rescuing the splenomegaly phenotype observed
in Map3k7DM/DM mice (data not shown). Specific ablation of
Mapk14 also restored disorganized splenic architectures ob-
served in Map3k7DM/DM mice (Figure 6A). In agreement with
these observations, the percentage (59.9%) of Gr-1+CD11b+
cells in the bone marrow of Map3k7DM/DM mice was reduced to
28.6% in Map3k7DM/DMMapk14DM/DM mice, similar to 29.6% in
WT mice (Figure 6B). Similarly, the percentage (9.5%) of neu-
trophils in Map3k7DM/DM spleen was decreased to 4.6% in
Map3k7DM/DMMapk14DM/DM spleen (Figure 6C). Interestingly,
specific ablation of Mapk14 in Map3k7DM/DM mice reduced the
population of activated CD69+ and IFN-g-producing T cells to
the same percentages observed in WT mice (Figures S3D and
S3E). The notion that Mapk14 deletion can reduce the hyper-
proliferation of neutrophils in Map3k7DM/DM mice was further
supported by results from in vivo BrdU pulse-labeling experi-
ments (Figure S3F). We found that apoptosis was similar in4, January 27, 2012 ª2012 Elsevier Inc. 47
Figure 5. Effects of TAK1 Ablation on Proinflam-
matoryCytokineProduction in aCell Type-Specific
Manner
(A and B) IL-6, TNF-a, and IL-1b secretion by neutrophils
(A) or peritoneal macrophages (B) treated with or without
LPS (100 ng/ml) for indicated time points was measured
by ELISA. IL-1b production was stimulated with ATP
(5 mM) for 1 hr.
(C) ELISA measurement of IL-6 production by MEFs after
LPS (1 mg/ml) treatment for 24 hr.
(D) Survival of WT and Map3k7DM/DM mice (n = 10 per
group) after high-dose LPS (30 mg/kg) challenge.
(E) Plasma concentrations of IL-6, TNF-a, and IL-1b in
mice at various times after LPS treatment.
Data shown are the mean ± SD. *p < 0.05; **p < 0.01;
***p < 0.001. Data shown are representative of at least five
independent experiments. See also Figure S2.
Immunity
TAK1 Inhibits NF-kB and p38 Signaling in NeutrophilsGr-1+CD11b+ neutrophils from WT, Map3k7DM/DM, and
Map3k7DM/DMMapk14DM/DM bone marrows and spleens (Fig-
ure S3G). In contrast, Mapk14 ablation restored the survival of
cultured TAK1-deficient BMMs similar to WT cells, as well as
cell proliferation based on CFSE labeling (Figures 6D, S3H,
and S3I). These results indicate that Mapk14 ablation reduces
proliferative expansion of neutrophils in the bone marrow and
spleen, meanwhile improving the survival of BMMs, thus
rescuing the splenomegaly, disorganized splenic histology and
hyperplasia, and abnormal cellularity observed in Map3k7DM/DM
mice.
Specific Deletion of Mapk14 Restores NF-kB Signaling
and Proinflammatory Cytokine Production
in Map3k7DM/DM Mice
We next tested whether the elevated NF-kB signaling and proin-
flammatory cytokine production seen in Map3k7DM/DM mice
were also reduced in Map3k7DM/DMMapk14DM/DM mice. In
response to LPS stimulation, Mapk14 deletion reduced the
LPS-induced elevated IKK phosphorylation as well as IkBa48 Immunity 36, 43–54, January 27, 2012 ª2012 Elsevier Inc.degradation observed in TAK1-deficient neutro-
phils (Figures 6E and S3J). Consistent with
these observations, mRNA and protein expres-
sion of IL-1b, IL-6, and TNF-a detected in
Map3k7DM/DMMapk14DM/DM neutrophils were
either partially or completely restored to similar
amounts observed in WT cells (Figures 6F
and S3K). These results suggest that Mapk14
deletion restores the increased IKK phos-
phorylation and cytokine production in TAK1-
deficient neutrophils to those in WT cells.
To determine the sensitivity of Map3k7DM/DM
Mapk14DM/DM mice to LPS-induced septic
shock, we treated WT, Map3k7DM/DM, and
Map3k7DM/DMMapk14DM/DM mice with LPS and
monitored their survival. As indicated in Fig-
ure 6G, Map3k7DM/DMMapk14DM/DM mice had
intermediate survival times compared with the
WT and Map3k7DM/DM groups, thus partially
rescuing mice from LPS-induced endotoxin
shock. Consistent with this observation, theplasma concentrations of IL-6, TNF-a, and IL-1b inMap3k7DM/DM
Mapk14DM/DM mice were completely restored to those in WT
mice, compared with Map3k7DM/DM mice (Figure 6H). Taken
together, these results clearly indicate that Mapk14 ablation in
myeloid cells can offset the increased production of inflammatory
cytokines and reduce the hypersensitivity to LPS-induced septic
shock seen inMap3k7DM/DM mice.
Multiple Signaling Pathways Lead to Increased
Phosphorylation of p38
We next sought to determine how p38 phosphorylation was
enhanced in TAK1-deficient neutrophils. Phosphorylation of
p38 is generally thought to be controlled by the activated TAK1
and TAB1-3 complex or MAPK-ERK kinase kinase (MEKK3,
Map3k3) (Ge et al., 2002). It has been reported that in addition
to its binding to TAK1 with high affinity, TAB1 can also directly
bind to p38a, resulting in enhanced phosphorylation of p38a
(Ge et al., 2002). Thus, we reasoned that loss of TAK1 in neutro-
phils might allow free TAB1 to bind to p38, thus increasing the
interaction between TAB1 and p38. Indeed, we observed
Figure 6. p38 Ablation Rescues Spleno-
megaly Phenotype and Increased Proin-
flammatory Signaling in TAK1-Deficient
Mice
(A) H&E staining of spleen sections from WT,
Map3k7DM/DM, and Map3k7DM/DMMapk14DM/DM
mice. Top, 1003 magnification; bottom, 4003
magnification.
(B and C) FACS analysis of Gr-1+CD11b+ neu-
trophils and F4/80+CD11b+ macrophages in
bone marrows (B) and spleens (C) from WT,
Map3k7DM/DM, and Map3k7DM/DMMapk14DM/DM
mice.
(D) Photographs of cultured BMM were visualized
by light microscopy and apoptotic cells were
analyzed by Annexin V/7-AAD staining and flow
cytometry. Results are representative of at least
three independent experiments.
(E) Immunoblot analysis of P-IKK, IkBa, and P-p38
in neutrophils treated with LPS for the indicated
time points.
(F) Real-time PCR analysis of IL-6, TNF-a, and
IL-1bmRNA expression in neutrophils treated with
LPS for the indicated time points.
(G) Survival ofWT (n = 4),Map3k7DM/DM (n = 4), and
Map3k7DM/DMMapk14DM/DM (n = 4) mice treated
with high-dose LPS (30 mg/kg).
(H) Serum concentrations of IL-6, TNF-a, and
IL-1b were measured at 1 and 3 hr after LPS
challenge.
Data shown in (G) and (H) are the mean ± SD.
*p < 0.05; **p < 0.01; ***p < 0.001. Data shown are
representative of at least five independent exper-
iments. See also Figure S3.
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TAK1 Inhibits NF-kB and p38 Signaling in Neutrophilsa stronger TAB1-p38 interaction in untreated TAK1-deficient
neutrophils compared with WT cells (Figure 7A). Although this
interaction was increased in WT neutrophils after LPS treatment,
a more robust increase in TAB1-p38 interaction was observed
in TAK1-deficient neutrophils (Figure 7A). By contrast, we
observed little or only weak TAB1-p38 interaction in WT and
TAK1-deficient MEFs, although this interaction was only slightly
increased in WT and TAK1-deficient macrophages after LPS
treatment (Figure 7A). To determine the functional significance
of TAB1-p38 interaction, we found that TAB1 could activate
endogenous and exogenous p38 phosphorylation but did not
activate IKK phosphorylation, whereas MEKK3 could stimulateImmunity 36, 43–5both IKK and p38 phosphorylation (Fig-
ure 7B). These results suggest that inter-
action between TAB1 and p38 is cell
type specific and is markedly enhanced
in TAK1-deficient neutrophils but not in
TAK1-deficient MEFs and macrophages.
We next sought to determine the rela-
tive contribution of MEKK3 to increased
p38 phosphorylation, because MEKK3
is an important kinase upstream of
p38 signaling (Huang et al., 2004). To
test this prediction, we simultaneously
deleted Map3k7 and Map3k3 by gener-
ating Map3k7flox/flox 3 Map3k3flox/flox 3
Lyz2-Cre (Map3k7DM/DMMap3k3DM/DM)mice. Specific deletion of Map3k3 partially reduced the spleno-
megaly observed inMap3k7DM/DMmice (Figure S4A), suggesting
that Map3k3 ablation affects the phenotype of Map3k7DM/DM
mice in developmental processes. However, specific ablation
of Map3k3 failed to reduce the increased phosphorylation of
IKK and p38 observed in Map3k7DM/DM mice (Figure 7C). Con-
sistent with this observation, the sensitivity of Map3k7DM/DM
Map3k3DM/DM mice to LPS-induced septic shock was almost
identical to that ofMap3k7DM/DM mice, which showed increased
sensitivity to LPS-induced septic shock compared with WTmice
(Figure 7D). We also observed that the plasma concentrations of
IL-6, TNF-a, and IL-1b inMap3k7DM/DMMap3k3DM/DM mice were4, January 27, 2012 ª2012 Elsevier Inc. 49
Figure 7. Multiple Pathways Are Involved in p38 Activation in TAK1-Deficient Neutrophils
(A) Interaction between TAB1 and p38 in neutrophils, peritoneal macrophages, and MEFs. Cells were treated with or without LPS for 15 min and cell lysates were
immunoprecipitated (IP) with anti-TAB1 followed by immunoblotting with anti-p38a and anti-TAB1.
(B) 293T cells were transfected with Flag-TAB1, HA-p38a, HA-MEKK3, or empty vector alone, followed by immunoblot analysis of cell lysates with indicated
antibodies.
(C) WT, Map3k7DM/DM, and Map3k7DM/DMMap3k3DM/DM neutrophils were treated with LPS, and cell lysates were immunoblotted with indicated antibodies.
(D) Survival ofWT (n = 5),Map3k7DM/DM (n = 4), andMap3k7DM/DMMap3k3DM/DM (n = 4)mice treated with high-dose LPS (25mg/kg). Serum concentrations of IL-6,
TNF-a, and IL-1b were measured at 0, 1, and 3 hr after LPS injection.
(E) Serum concentrations of IL-6, TNF-a, and IL-1b were measured at 1 hr and 3 hr after LPS challenge.
(F) WT,Map3k7DM/DM,Map3k7DM/DMMapk14DM/DM, andMap3k7DM/DMMap3k3DM/DM neutrophils were pretreated with or without NAC (5 mM) for 30 min followed
by LPS stimulation for 3 hr. ROS production was measured by staining cells with CM-H2DCFDA for 30 min followed by flow cytometry.
Results are representative of at least three independent experiments. See also Figure S4.
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TAK1 Inhibits NF-kB and p38 Signaling in Neutrophilssimilar to those inMap3k7DM/DMmice but were higher than those
in WT mice (Figure 7E). These results suggest that specific
deletion of Map3k3 partially reduces the splenomegaly of
Map3k7DM/DM mice but fails to reduce increased phosphoryla-
tion of IKK and p38 after LPS treatment or increased sensitivity
to LPS-induced septic shock in Map3k7DM/DM mice.50 Immunity 36, 43–54, January 27, 2012 ª2012 Elsevier Inc.Recent studies show that reactive oxygen species (ROS) can
also stimulate phosphorylation of p38 and IKK (Kulisz et al.,
2002; Matsuzawa et al., 2005). In particular, LPS-induced pro-
duction of ROS selectively activates p38 phosphorylation via
an ASK1 (apoptosis signaling regulated kinase 1)-dependent
manner (Matsuzawa et al., 2005). To test whether TAK1 deletion
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TAK1 Inhibits NF-kB and p38 Signaling in Neutrophilsmay result in increased ROS production, we treated neutrophils
and macrophages with LPS for 30 and 180 min and then incu-
bated cells with CM-H2DCFDA for 30 min. ROS production in
cells without LPS served as control. Flow cytometry analysis
revealed markedly increased ROS production in TAK1-deficient
neutrophils, compared to WT cells after LPS treatment (Fig-
ure S4B). In contrast, ROS production was lower in TAK1-defi-
cient macrophages than in WT cells after LPS stimulation (Fig-
ure S4C). To determine whether specific deletion of Mapk14 or
Map3k3 affects ROS production in TAK1-deficient neutrophils,
we isolated neutrophils from WT, Map3k7DM/DM, Map3k7DM/DM
Mapk14DM/DM, and Map3k7DM/DMMap3k3DM/DM mice and then
measured ROS production after LPS treatment. As shown in Fig-
ure 7F, LPS-induced ROS production in TAK1-deficient neutro-
phils was much higher than that in WT cells. However, Mapk14
but not Map3k3 deletion reduced the amounts of LPS-induced
ROS production in TAK1-deficient neutrophils to the amounts
seen without LPS treatment, consistent with reduced IKK
phosphorylation inMap3k7DM/DMMapk14DM/DM neutrophils (Fig-
ure S3J). Treatment of cells with the ROS inhibitor N-acetyl-L-
cysteine (NAC) completely abolished total (LPS-dependent
and -independent) ROS production and phosphorylation of
IKK and p38 in all cells regardless of the source (Figures 7F
and S4D). To determine whether ROS production is responsible
for increased IKK phosphorylation, we treated neutrophils from
WT, Map3k7DM/DM, and Map3k7DM/DMMapk14DM/DM mice with
an organic H2O2 (tertiary butyl hydroperoxide, tBHP) and found
that exogenous ROS treatment rapidly increased IKK and p38
phosphorylation as well as NF-kB-responsive genes such as
IL-6 in neutrophils, regardless of the state of TAK1 and p38
(Figures S4E and S4F). Furthermore, tBHP treatment restored
IKK phosphorylation in Map3k7DM/DMMapk14DM/DM neutrophils
to similar amounts observed in Map3k7DM/DM neutrophils, com-
pared with those in cells treated with LPS alone (Figure S4E).
These results clearly suggest that ROS production is responsible
for increased IKK phosphorylation.
DISCUSSION
In this study we have shown that specific deletion of Map3k7 in
the myeloid lineage leads to splenomegaly, lymphadenopathy,
and increased percentages of Gr-1+CD11b+ neutrophils. Hyper-
proliferation and increased inflammatory cytokine production in
TAK1-deficient neutrophils, but not macrophages, stands in
sharp contrast to the increased cell death observed in mice
with conditional inactivation of TAK1 in hematopoietic lineages,
liver, and intestine epithelial cells (Bettermann et al., 2010; Inoku-
chi et al., 2010; Kajino-Sakamoto et al., 2008; Liu et al., 2006;
Tang et al., 2008). Importantly, we have demonstrated that
Map3k7 deletion in neutrophils enhanced activation of NF-kB,
p38, and JNK signaling after LPS stimulation. Notably, NF-kB
and p38 signaling was only slightly reduced in TAK1-deficient
peritoneal macrophages after TLR stimulation, in contrast to
TAK1-deficient MEFs, where NF-kB and p38 signaling and cyto-
kine response were completely abolished. However, Map3k7
deletion caused the apoptotic death of BMMs after 3 days of
culture. Taken together, these results clearly indicate that
TAK1 plays important roles in NF-kB, p38, and JNK signaling
pathways in a cell type-specific manner: TAK1 functions asa negative regulator of the IKK, p38, and JNK signaling pathways
in neutrophils but serves as an essential and positive regulator in
macrophages and fibroblasts.
We have further shown that TAK1-deficient Gr-1+CD11b+
neutrophils produce more IL-1b, IL-6, and TNF-a than WT cells
after LPS treatment. Although the numbers of B and T cells
were not changed in Map3k7DM/DM mice, further experiments
showed elevated percentages of activated T cells, suggesting
that larger amounts of proinflammatory cytokines may promote
T cell activation in Map3k7DM/DM mice. By contrast, IL-6 and
TNF-a production in TAK1-deficient macrophages was similar
or reduced after LPS treatment, but IL-1b production was
increased in TAK1-deficient peritoneal macrophages compared
withWT cells, whichmight be due to increased cell apoptosis, as
shown in IKKb-deficient macrophages (Greten et al., 2007).
Although most negative regulators of innate immune signaling
molecules, including A20, NLRC5, and NLRX1, inhibit NF-kB
signaling in most cell types (Allen et al., 2011; Cui et al., 2010;
Wertz et al., 2004; Xia et al., 2011), cell type-specific regulators
have been reported for other innate immune adaptor molecules
like RIG-I and MDA5, as well as IRF7 (Honda and Taniguchi,
2006; Kato et al., 2005, 2006). TRAF family member-associated
NF-kB activator (TANK) has been implicated in positive regula-
tion of transcriptional factors IRF3 and NF-kB. However, a recent
study showed that TANK-deficient mice develop splenomegaly
and lymphadenopathy and enhance NF-kB signaling by pro-
moting the ubiquitination of TRAF6 upon TLR stimulation, thus
serving as a negative regulator of TLR signaling (Matsushita
et al., 2009). In light of these findings, we conclude that TAK1
is another crucial (either positive or negative) regulator of
NF-kB and MAPK signaling in a cell type-specific manner.
Downregulation of NF-kB activation resulting from specific
Ikbkb (IKKb) inactivation in myeloid cells has been shown to
enhance IL-1b production and promote rapid LPS-induced
septic shock through a mechanism involving NF-kB-dependent
modulation of protease inhibitors (Greten et al., 2007). However,
Ikbkbflox/flox 3 Lyz2-Cre mice do not develop phenotypes such
as splenomegaly and neutrophilia observed in Map3k7DM/DM
mice (Greten et al., 2007). Because we found that TAK1-deficient
neutrophils increased NF-kB and MAPK signaling and produced
more IL-1b, IL-6, and TNF-a compared with WT cells, NF-kB-
dependent expression of protease inhibitors, which explains
the increased IL-1b processing in IKKb-deficient neutrophils
(Greten et al., 2007), could not fully explain the enhanced pro-
duction of IL-1b in TAK1-deficient neutrophils. Therefore, we
sought to identify alternative mechanisms. We have provided
compelling genetic evidence that Mapk14 deletion in myeloid
cells rescues the observed phenotypes and the inflammatory
cytokine responses in Map3k7DM/DM mice. Thus, it appears
that increased activation of p38 in TAK1-deficient cells is one
possible reason for the increased production of IL-1b, IL-6,
and TNF-a. These results are supported by previous findings
that p38 plays a critical role in inflammatory responses and trans-
lational regulation of IL-1b, IL-6, and TNF-a (Han and Ulevitch,
2005; Kang et al., 2006). Consistent with these observations,
the hypersensitivity to LPS-induced septic shock in Map3k7
and Mapk14 double-ablated mice was reduced, compared
with TAK1 single mutant mice. Thus, our results suggest that
although TAK1 deletion affects the phosphorylation of IKK,Immunity 36, 43–54, January 27, 2012 ª2012 Elsevier Inc. 51
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critical for the observed phenotypes and cytokine production
in Map3k7DM/DM mice.
To identify the molecular mechanisms by which TAK1 deletion
in neutrophils increases the phosphorylation of p38, we have
provided several lines of evidence that p38 can be activated
and phosphorylated by three distinct signaling pathways. First,
several studies have shown that whereas TAB1 binds to TAK1
with high affinity, TAB1 can also directly bind to p38a, resulting
in enhanced phosphorylation and activation of p38a (Ge et al.,
2002). To determine how TAK1 deletion affects p38 activation
in neutrophils, we found that TAB1-p38 interaction wasmarkedly
increased in unstimulated and LPS-stimulated TAK1-deficient
neutrophils. By contrast, we did not observe such an interaction
in MEFs or macrophages even after LPS stimulation. In addition,
we have shown that TAB1 can functionally stimulate p38, but not
IKK, phosphorylation. Thus, it is possible that loss of TAK1 in
neutrophils may free TAB1 to bind and stimulate p38 phosphor-
ylation, but not in MEFs or macrophages. Second, because
MEKK3 can also activate IKK and p38 phosphorylation, we
generated Map3k7 and Map3k3 double-ablated mice. Specific
deletion ofMap3k3 partially reduced the splenomegaly observed
in Map3k7DM/DM mice, suggesting that MEKK3 may partially
contribute to the developmental phenotype of Map3k7DM/DM
mice. However, neither increased IKK and p38 phosphorylation
after LPS stimulation nor increased sensitivity to LPS-induced
septic shock observed in Map3k7DM/DM mice changed in
Map3k7DM/DMMap3k3DM/DM mice. This would indicate that
MEKK3 might not be primarily responsible for increased IKK
and p38 phosphorylation in TAK1-deficient neutrophils after
LPS treatment. Third, our results showed that specific deletion
of p38 reduced the LPS-induced elevated IKK phosphorylation
as well as IkBa degradation observed in TAK1-deficient neutro-
phils. Thus, there are two key questions that remain to be ad-
dressed. (1) How is IKK activated? (2) How does p38 affect IKK
activation in TAK1-deficient neutrophils after LPS treatment?
To address these issues, we show that TAK1 deletion led to an
increase in LPS-induced ROS production in neutrophils, but
not in macrophages. Several recent studies demonstrate that
LPS-induced ROS can promote IKK and p38 phosphorylation
(Asehnoune et al., 2004; Ito et al., 2006; Kulisz et al., 2002; Mat-
suzawa et al., 2005). The fact that p38 phosphorylation by LPS-
induced ROS selectively requires ASK1, but not MEKK3 adaptor
molecule (Matsuzawa et al., 2005; Su, 2005), may explain why
Map3k3 deletion failed to reduce increased IKK and p38 phos-
phorylation observed in Map3k7DM/DM mice. Indeed, treatment
of neutrophils with NAC completely inhibited ROS production
and abolished IKK and p38 phosphorylation. Conversely, treat-
ment of neutrophils with exogenous H2O2 (tBPH) activated IKK
phosphorylation, regardless of genetic state of TAK1 and/or
p38. Our results further show that increase in LPS-induced
ROS production after treatment required active p38, because
deletion of p38 failed to increase ROS production, thus reducing
IKK phosphorylation. However, this phenomenon could be re-
versed by treatment of neutrophils with tBPH, suggesting that
ROS production is important for IKK phosphorylation. Although
TAK1 deletion in keratinocytes also increases ROS production,
the mechanisms responsible for increased ROS production
may be different (Lam et al., 2011). Thus, further studies are52 Immunity 36, 43–54, January 27, 2012 ª2012 Elsevier Inc.needed to elucidate how TAK1 ablation affects ROS production
induced by different stimuli.
On the strength of the above findings and published results,
we propose a workingmodel that TAK1 ablation enhances rather
than diminishes innate immune signaling in neutrophils (Fig-
ure S5). Upon LPS treatment, both WT and TAK1-deficient
neutrophils produce LPS-specific ROS (in addition to normal
metabolic ROS), which activates IKK and p38 phosphorylation
in neutrophils, regardless of the state of TAK and p38. However,
the differences in IKK and p38 phosphorylation betweenWT and
TAK1-deficient neutrophils after LPS treatment may begin with
the intrinsic shift from TAB1 interaction with TAK1 to TAB inter-
action with p38 in TAK1-deficient neutrophils. Free TAB1 in
TAK1-deficient neutrophils enhances or amplifies p38 phos-
phorylation, in contrast to TAB1 in WT cells, which mainly binds
to TAK1. This delicate shift may lead to increased phosphoryla-
tion of p38 and production of downstream responsive genes
such as IL-6 in TAK1-deficient neutrophils. Increased production
of proinflammatory cytokines may further increase ROS produc-
tion through cytokine receptor signaling pathways, thus forming
a positive regulatory mechanism or loop (ROS/p38/ROS). It
should be noted that this is an active and ongoing process.
The difference in IKK phosphorylation between WT and TAK1-
deficient neutrophils after LPS treatment may be due to differ-
ences in ROS production that induces IKK phosphorylation.
Specific deletion of p38 disrupts this positive feedback regula-
tory loop, thus reducing ROS production, restoring IKK phos-
phorylation in TAK1-deficient neutrophils to similar amounts
observed in WT cells, and rescuing the phenotypes observed
in Map3k7DM/DM mice. By contrast, specific deletion of Map3k3
fails to do so, although MEKK3 can activate both IKK and p38
activation during developmental processes.
In conclusion, we clearly demonstrate that TAK1 negatively
regulates proinflammatory signaling cascades and cytokine
production in neutrophils, but not in macrophages, thus pro-
viding genetic and biochemical evidence that TAK1 regulates
NF-kB and MAPK signaling pathways in a cell type-specific
manner. More importantly, p38 is a key downstream signaling
molecule that controls inflammatory signaling and maintains
homeostasis of innate immune cells, particularly inMap3k7DM/DM
mice. We also provide evidence that increased ROS production
and increased TAB1-p38 interaction in TAK1-deficient neutro-
phils may contribute to increased p38 and IKK phosphorylation
as well as the production of proinflammatory cytokines after
LPS stimulation, whereas MEKK3 may be involved in controlling
homeostasis of immune responses during development. Thus,
these findings identify a previously unrecognized role of TAK1
in negative regulation of innate immune signaling in neutrophils
and could have important implications for development of ther-
apies for inflammation-associated diseases, including cancer.
EXPERIMENTAL PROCEDURES
Animals
Map3k7flox/flox mice (gift from M.D. Schneider, Baylor College of Medicine)
were crossed with lysozyme-Cre (Lyz2-Cre) mice (Jackson Laboratory)
to obtain Map3k7DM/DM mice in the C57BL/6 background. To generate
Map3k7DM/DMMapk14DM/DM mice, Map3k7DM/DM mice were bred with
Mapk14flox/flox mice (provided by Y. Wang, UCLA, and H. Jiang, Boehringer-
Ingelheim) (Engel et al., 2005). To generate Map3k7DM/DMMap3k3DM/DM mice,
Immunity
TAK1 Inhibits NF-kB and p38 Signaling in NeutrophilsMap3k7DM/DM mice were bred with Map3k3flox/flox mice. Studies were per-
formed with 8- to 12-week-old mice. Animal experiments were approved
by the Institutional Animal Care and Use Committee of Baylor College of
Medicine. To study in vivo endotoxicity, mice received i.p. injection of LPS
(25–30 mg/kg) and blood samples were collected to assay plasma cytokine
concentrations.
Primary Cell Cultures
Bone marrow-derived macrophages (BMM) were generated by flushing bone
marrow cells from femurs and tibiae of mice. Cells were cultured in RPMI
media containing 10% FBS and 1% (volume/volume) penicillin-streptomycin
supplemented with 10% M-CSF conditioned media. Peritoneal macrophages
were obtained by injectingmicewith 4% (v/v) thioglycollate (Beckton Dickson),
and peritoneal cavities were flushed after 3 days with RPMI media/2% FBS.
TAK1 WT and deficient MEFs were a generous gift from D. Zhang (Texas
A&M University). Neutrophils were obtained from the peritoneal cavity by
injecting mice with 2 ml 4% (v/v) thioglycollate for 4 hr followed by collection
of peritoneal exudates with RPMI media/2% FBS. Cells were stained with
anti-Gr-1-PE (eBioscience) and purified with PE-positive selection magnetic
beads (Stem Cell Technologies).
Immunoprecipitation and Immunoblot Analyses
For immunoprecipitation, cell lysates were incubatedwith indicated antibodies
and protein A and G beads (Pierce) overnight. Beads were washed four times
with lysis buffer, and immunoprecipitates were eluted with SDS loading buffer.
Immunoblotting was performed by resolving protein lysates on SDS-PAGE
gels, followed by a transfer to PVDFmembranes (Bio-Rad) and then incubating
membranes with indicated antibodies overnight. For all blots, LumiGlo Chemi-
luminescent Substrate System from KPL (Gaithersburg, MD) was used for
protein detection.
Flow Cytometry
Cell surface staining, intracellular cytokine staining, flow cytometry, and cell
sorting were performed as described previously (Wang et al., 2004; Ivanov
et al., 2006; Miyahara et al., 2008). Single-cell suspensions were obtained
from tissues and stained for 30 min with indicated antibodies. Flow cytometric
analysis was performed with BD FACS Calibur or BD FACS Aria (Becton
Dickson).
Cytokine Release Assay
Cell supernatants or sera were collected at indicated time points after stimu-
lation with LPS with or without ATP. Cytokine concentrations were measured
by ELISAwith anti-mouse IL-6 antibodies (Thermo Scientific), TNF-a and IL-1b
ELISA kits purchased from R&D Systems. ELISA assays were performed
according to the manufacturer’s instructions.
ROS Measurement and H2O2 Treatment
Neutrophils were pretreated with or without NAC (5mM) for 30min followed by
stimulation with LPS (100 ng/ml) for 0, 10, 30 min, and 3 hr at 37C. Cells were
harvested and incubated with or without CM-H2DCFDA (10 mM) in PBS for
30 min at 37C and cells were analyzed by flow cytometry. Similarly, neutro-
phils from WT, Map3k7DM/DM, or Map3k7DM/DMMapk14DM/DM mice were
treated with an organic form of H2O2 (tertiary butyl hydroperoxide, tBHP),
LPS, or both for 0, 10, and 30 min and then used to determine IKK and p38
phosphorylation by immunoblot.
Hematological and Histological Analysis
Complete blood counts were performed with an automated hematology
analyzer (Hemavet 850; Drew Scientific). For histology, tissues were
formalin-fixed, processed, and paraffin-embedded. H&E staining was done
by the Breast Cancer Center (Baylor College of Medicine).
Statistical Analysis
Data are represented as mean ± SD when indicated and Student’s t test was
used for all statistical analyses with the GraphPad Prism 4.0 software. Differ-
ences were considered significant when p value was less than 0.05.SUPPLEMENTAL INFORMATION
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